JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation — Stella

Recruiting

Back to Solid Tumors trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(13 sites)

United States

Research Site, Denver, Colorado

Research site, Lake Mary, Florida

Research site, St Louis, Missouri

Research site, Canton, Ohio

Research site, Cleveland, Ohio

Key details

Phase

Safety & dosing

Sponsor

Jacobio Pharmaceuticals Co., Ltd.

Enrollment target

~144 participants

Started

July 2024

Primary completion

January 2027

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov